Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul 1;67(7):ezaf175.
doi: 10.1093/ejcts/ezaf175.

Extent of coronary artery disease and clinical outcomes with ticagrelor monotherapy versus aspirin after coronary artery bypass grafting: insights from the TiCAB trial

Melanie Arnreiter  1 , Moritz von Scheidt  2   3 , Johannes M Albes  4 , Tim Attmann  5 , Andreas Boening  6 , Yeong-Hoon Choi  7 , Lenard Conradi  8 , Bernhard C Danner  9 , Andreas Fach  10 , Ivar Friedrich  11 , Herko Grubitzsch  12 , Roland Heck  12 , Alexander Joost  13 , Christoph Knosalla  12 , Martin Misfeld  14 , Martin Oberhoffer  15 , Julia Riebandt  1 , Andreas Schaefer  16 , Matthias Siepe  17 , Thomas Walther  18 , Gerhard Wimmer-Greinecker  19 , Uwe Zeymer  20 , Heribert Schunkert  2   3 , Adnan Kastrati  2   3 , Sigrid Sandner  1
Affiliations
Clinical Trial

Extent of coronary artery disease and clinical outcomes with ticagrelor monotherapy versus aspirin after coronary artery bypass grafting: insights from the TiCAB trial

Melanie Arnreiter et al. Eur J Cardiothorac Surg. .

Abstract

Objectives: Patients with extensive coronary artery disease (CAD) have a higher risk of cardiovascular events. This post hoc analysis of the Ticagrelor in CABG (TiCAB) trial examined the association of ticagrelor monotherapy versus aspirin with clinical outcomes after coronary artery bypass grafting (CABG) in relation to the extent of CAD.

Methods: The TiCAB trial randomized CABG patients to ticagrelor (90 mg twice daily) or aspirin (100 mg daily) for 12 months. Patients were stratified by SYNTAX score terciles: low (≤22), intermediate (23-32) and high (≥33). The primary end-point was major adverse cardiac and cerebrovascular events (MACCE) at 12 months, including cardiovascular death, myocardial infarction, stroke or repeat revascularization. Secondary end-points included individual MACCE components and major bleeding events. Cox proportional hazards models were used to assess treatment effects.

Results: Among 752 patients, 33.4% had low, 36.0% intermediate and 30.6% high SYNTAX scores (median 26.5 [20.0-33.0]). MACCE rates were similar across groups (low: 7.8%; intermediate: 9.2%; high: 8.8%; P = 0.87), though the incidence of repeat revascularization differed significantly among SYNTAX score groups (P = 0.02). Ticagrelor did not show a significant MACCE benefit over aspirin in any SYNTAX score group (low: HR 2.27, 95% CI 0.87-5.94; intermediate: HR 1.02, 95% CI 0.46-2.27; high: HR 1.76, 95% CI 0.70-4.46; Pint=0.41). Secondary outcomes, including bleeding, aligned with overall trial results.

Conclusions: This analysis did not find a differential benefit of ticagrelor versus aspirin across CAD complexity levels as measured by the SYNTAX score. Further studies are warranted to refine antiplatelet strategies for patients with complex CAD undergoing CABG.

Keywords: Aspirin; Complex coronary artery disease; Coronary artery bypass grafting; SYNTAX score; Ticagrelor.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1:
Figure 1:
Cumulative event rate curves for the composite primary outcome of cardiovascular death, myocardial infarction, stroke or repeat revascularization by SYNTAX score terciles.
Figure 2:
Figure 2:
Forest plot showing efficacy and safety outcomes at 12 months by SYNTAX score terciles (low [≤22], intermediate [23–32], high [≥33]) and randomized treatment. *Insufficient number of events in 1 or both treatment groups.
Figure 3:
Figure 3:
Cumulative event rate curves for the composite primary outcome of cardiovascular death, myocardial infarction, stroke or repeat revascularization by SYNTAX score terciles and randomized treatment: (A) low (≤22) SYNTAX score; (B) intermediate (23–32) SYNTAX score; (C) high (≥33) SYNTAX score.
See this image and copyright information in PMC

References

    1. Ikeno F, Brooks MM, Nakagawa K et al. ; BARI-2D Study Group. SYNTAX score and long-term outcomes. J Am Coll Cardiol 2017;69:395–403. doi: 10.1016/j.jacc.2016.10.067 - DOI - PubMed
    1. Reynolds HR, Shaw LJ, Min JK et al. Outcomes in the ISCHEMIA trial based on coronary artery disease and ischemia severity. Circulation 2021;144:1024–38. doi: 10.1161/CIRCULATIONAHA.120.049755 - DOI - PMC - PubMed
    1. Steg PG, Bhatt DL, Simon T et al. ; THEMIS Steering Committee and Investigators. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med 2019;381:1309–20. doi: 10.1056/NEJMoa1908077 - DOI - PubMed
    1. Bonaca MP, Bhatt DL, Cohen M et al. ; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–800. doi: 10.1056/NEJMoa1500857 - DOI - PubMed
    1. Valgimigli M, Gragnano F, Branca M et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ 2021;373:n1332. doi: 10.1136/bmj.n1332 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources